Compare Stocks

Date Range: 

 CRISPR TherapeuticsNeurocrine BiosciencesAcceleron PharmaFate TherapeuticsTwist Bioscience
SymbolNASDAQ:CRSPNASDAQ:NBIXNASDAQ:XLRNNASDAQ:FATENASDAQ:TWST
Price Information
Current Price$107.70$91.04$118.18$76.49$116.74
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.72.31.81.81.4
Analysis Score4.34.34.44.42.2
Community Score2.73.63.03.02.5
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.01.90.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$160.88$127.83$148.21$110.47$137.50
% Upside from Price Target49.37% upside40.41% upside25.41% upside44.42% upside17.78% upside
Trade Information
Market Cap$8.16 billion$8.61 billion$7.17 billion$7.18 billion$5.68 billion
Beta2.371.010.591.880.83
Average Volume2,090,2481,115,048371,8171,032,967947,216
Sales & Book Value
Annual Revenue$289.59 million$788.10 million$73.99 million$10.68 million$90.10 million
Price / Sales28.1810.9296.95672.4563.03
Cashflow$0.70 per share$0.57 per shareN/AN/AN/A
Price / Cash154.11158.60N/AN/AN/A
Book Value$17.02 per share$6.92 per share$8.47 per share$3.24 per share$7.53 per share
Price / Book6.3313.1613.9523.6115.50
Profitability
Net Income$66.86 million$37.01 million$-124,860,000.00$-98,150,000.00$-139,930,000.00
EPS$1.17$0.39($2.38)($1.44)($3.00)
Trailing P/E RatioN/A97.89N/AN/AN/A
Forward P/E RatioN/A25.15N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-273.10%8.96%-157.84%-810.13%-155.31%
Return on Equity (ROE)-20.72%18.18%-31.62%-35.51%-44.62%
Return on Assets (ROA)-18.35%9.50%-28.11%-25.40%-35.49%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio16.53%1.89%12.02%9.17%9.29%
Quick Ratio16.53%1.86%12.02%9.17%8.95%
Ownership Information
Institutional Ownership Percentage66.43%95.25%79.78%99.67%87.90%
Insider Ownership Percentage17.10%4.30%2.50%21.41%7.00%
Miscellaneous
Employees410845312279525
Shares Outstanding75.77 million94.54 million60.70 million93.89 million48.65 million
Next Earnings Date7/26/2021 (Estimated)8/2/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 RevenueTwist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
streetwisereports.com - May 7 at 4:44 PM
Twist Bioscience (NASDAQ:TWST) Shares Gap Up to $104.30Twist Bioscience (NASDAQ:TWST) Shares Gap Up to $104.30
americanbankingnews.com - May 7 at 11:08 AM
Twist Bioscience (NASDAQ:TWST) Releases FY 2021 Earnings GuidanceTwist Bioscience (NASDAQ:TWST) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 6 at 10:36 PM
Twist Bioscience Reports Second Quarter Fiscal 2021 Financial ResultsTwist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
uk.finance.yahoo.com - May 6 at 7:01 PM
Twist Bioscience: Fiscal Q2 Earnings SnapshotTwist Bioscience: Fiscal Q2 Earnings Snapshot
sfgate.com - May 6 at 7:01 PM
Twist Bioscience Enters Oversold Territory (TWST)Twist Bioscience Enters Oversold Territory (TWST)
nasdaq.com - May 6 at 7:01 PM
Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $317,187.78 in StockTwist Bioscience Co. (NASDAQ:TWST) Insider Sells $317,187.78 in Stock
americanbankingnews.com - May 6 at 5:46 PM
Why Does Cathie Wood Like This Healthcare Stock So Much?Why Does Cathie Wood Like This Healthcare Stock So Much?
finance.yahoo.com - May 6 at 8:59 AM
Twist Bioscience (NASDAQ:TWST) and Seneca Biopharma (NASDAQ:SNCA) Head-To-Head ComparisonTwist Bioscience (NASDAQ:TWST) and Seneca Biopharma (NASDAQ:SNCA) Head-To-Head Comparison
americanbankingnews.com - May 5 at 7:14 PM
Notable Two Hundred Day Moving Average Cross - TWSTNotable Two Hundred Day Moving Average Cross - TWST
nasdaq.com - May 4 at 4:46 PM
Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.5%Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.5%
americanbankingnews.com - May 3 at 1:34 PM
Twist Bioscience Corporation (NASDAQ:TWST) is expected to hit 200 USD!Twist Bioscience Corporation (NASDAQ:TWST) is expected to hit 200 USD!
stocksregister.com - May 1 at 6:35 PM
Is a Beat in the Cards for Twist (TWS) This Earnings Season?Is a Beat in the Cards for Twist (TWS) This Earnings Season?
finance.yahoo.com - April 29 at 6:14 PM
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - April 29 at 6:14 PM
Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR ApplicationsTwist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications
finance.yahoo.com - April 28 at 12:04 PM
At Current Prices, Twist Bioscience Corporation (NASDAQ:TWST) Worth A Patient Look?At Current Prices, Twist Bioscience Corporation (NASDAQ:TWST) Worth A Patient Look?
marketingsentinel.com - April 24 at 9:44 AM
Pure Biologics partnership fails to invigorate Twist Bioscience’s share pricePure Biologics partnership fails to invigorate Twist Bioscience’s share price
cmcmarkets.com - April 23 at 10:33 PM
Twist Bioscience Corp (TWST) COO Patrick Weiss Sold $610,404 of SharesTwist Bioscience Corp (TWST) COO Patrick Weiss Sold $610,404 of Shares
ca.finance.yahoo.com - April 23 at 10:33 PM
2 Cathie Wood Stocks to Buy, 2 to Sell2 Cathie Wood Stocks to Buy, 2 to Sell
stocknews.com - April 22 at 3:42 PM
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
finance.yahoo.com - April 22 at 10:42 AM
First Week of June 18th Options Trading For Twist Bioscience (TWST)First Week of June 18th Options Trading For Twist Bioscience (TWST)
nasdaq.com - April 20 at 2:50 PM
Twist Bioscience (NASDAQ:TWST) Shares Gap Down to $135.24Twist Bioscience (NASDAQ:TWST) Shares Gap Down to $135.24
americanbankingnews.com - April 19 at 12:02 PM
Piper Sandler Initiates Coverage on Twist Bioscience (NASDAQ:TWST)Piper Sandler Initiates Coverage on Twist Bioscience (NASDAQ:TWST)
marketbeat.com - April 19 at 9:22 AM
Twist Bioscience (NASDAQ:TWST) Coverage Initiated at Piper SandlerTwist Bioscience (NASDAQ:TWST) Coverage Initiated at Piper Sandler
americanbankingnews.com - April 19 at 9:16 AM
Twist Bioscience to Expand Oregon Lease, Supporting Future GrowthTwist Bioscience to Expand Oregon Lease, Supporting Future Growth
finance.yahoo.com - April 16 at 1:01 PM
Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,000 SharesTwist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,000 Shares
americanbankingnews.com - April 15 at 10:52 AM
Twist Bioscience (NASDAQ:TWST) Lifted to Hold at Zacks Investment ResearchTwist Bioscience (NASDAQ:TWST) Lifted to Hold at Zacks Investment Research
marketbeat.com - April 8 at 6:44 AM
DateCompanyBrokerageAction
4/27/2021CRISPR TherapeuticsJefferies Financial GroupUpgrade
4/27/2021CRISPR TherapeuticsBarclaysBoost Price Target
3/10/2021CRISPR TherapeuticsJMP SecuritiesInitiated Coverage
2/17/2021CRISPR TherapeuticsThe Goldman Sachs GroupLower Price Target
2/17/2021CRISPR TherapeuticsOppenheimerBoost Price Target
2/17/2021CRISPR TherapeuticsChardan CapitalBoost Price Target
2/17/2021CRISPR TherapeuticsNeedham & Company LLCReiterated Rating
1/12/2021CRISPR TherapeuticsTruistBoost Price Target
12/10/2020CRISPR TherapeuticsPiper SandlerBoost Price Target
12/7/2020CRISPR TherapeuticsStifel NicolausBoost Price Target
12/7/2020CRISPR TherapeuticsCanaccord GenuityBoost Price Target
12/7/2020CRISPR TherapeuticsRoth CapitalBoost Price Target
12/7/2020CRISPR TherapeuticsWells Fargo & CompanyDowngrade
10/30/2020CRISPR TherapeuticsRaymond JamesReiterated Rating
5/6/2021Neurocrine BiosciencesWedbushLower Price Target
5/6/2021Neurocrine BiosciencesMorgan StanleyLower Price Target
5/6/2021Neurocrine BiosciencesSVB LeerinkLower Price Target
5/3/2021Neurocrine BiosciencesMizuhoLower Price Target
3/5/2021Neurocrine BiosciencesRobert W. BairdReiterated Rating
1/26/2021Neurocrine BiosciencesWilliam BlairReiterated Rating
12/29/2020Neurocrine BiosciencesCantor FitzgeraldLower Price Target
11/10/2020Neurocrine BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
11/10/2020Neurocrine BiosciencesSmith Barney CitigroupLower Price Target
3/17/2021Acceleron PharmaWolfe ResearchInitiated Coverage
1/29/2021Acceleron PharmaJPMorgan Chase & Co.Boost Price Target
1/19/2021Acceleron PharmaHC WainwrightBoost Price Target
2/26/2021Fate TherapeuticsBank of AmericaInitiated Coverage
1/25/2021Fate TherapeuticsBMO Capital MarketsBoost Price Target
7/8/2020Twist BioscienceCowenReiterated Rating
2/7/2020Twist BioscienceEvercore ISIInitiated Coverage
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.